Navigation Links
Mylan Launches First Generic Version of Xopenex(R) Inhalation Solution (Concentrate), 0.25%
Date:9/1/2009

PITTSBURGH, Sept. 1 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched levalbuterol inhalation solution USP (Concentrate), 0.25%, (1.25 mg/0.5 mL). Mylan, which has already launched the product, will market this product with 180 days of exclusivity.

This product, which is indicated for the treatment or prevention of bronchospasm in patients over 6 years old with reversible obstructive airway disease, is the first generic version of Sepracor Inc.'s Xopenex(R) Inhalation Solution (Concentrate), 0.25%, to be approved by the U.S. Food and Drug Administration (FDA). According to IMS Health, Xopenex Inhalation Solution (Concentrate), 0.25% had total U.S. sales of approximately $18.3 million for the 12 months ending June 30, 2009.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; operates a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and runs a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Begins Marketing First Generic Version of BenzaClin(R) Acne Treatment
2. Mylans Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment
3. Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48-Year Exemplary Record of Quality
4. President Clinton and Mylan Chairman and CEO Robert J. Coury Announce New Agreement to Lower Price of Treatment for Patients with Drug-Resistant HIV in Developing Countries
5. Mylan Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Closing Bell
6. Mylan Announces Enhancements to Executive Management Team
7. Mylan Reports That the FDA Determined That All Accusations Were Unfounded
8. Mylan Reiterates and Stands Behind Its 48-Year Commitment and Track Record of Quality
9. Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
10. Mylan Declares Quarterly Preferred Stock Dividend
11. Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 21, 2017 , ... San Diego physician and surgeon ... reform plan, has announced his candidacy for the 52nd Congressional District currently held by ... America’s Promise. Coming to this country at age eleven after suffering homelessness and hardship ...
(Date:8/20/2017)... Calif. (PRWEB) , ... August 20, 2017 , ... A total solar eclipse ... for a few minutes as the moon moves between the sun and Earth. This rare ... , These four tips can help keep you safe on the road during the total ...
(Date:8/20/2017)... CO (PRWEB) , ... August 20, 2017 , ... Are ... the same household? If so, you may be interested in participating in a ... purpose of this research is to understand more about the relational aspects of adults ...
(Date:8/19/2017)... California (PRWEB) , ... August 18, 2017 , ... ... a partnership aimed at creating a transparent, verifiable database to help the cannabis ... distributed ledger technology, Paragon hopes to deliver a faster technology with lower fees. ...
(Date:8/19/2017)... ... , ... Curl Keeper® is excited to announce that the H2O Water Bottle ... for the second year in a row. The H2O Bottle, a refillable ultra-fine spray ... Moisturizer for Type 2 Wavies and Best Refresher for Type 2 Wavies in 2017. ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... 2017   Second-quarter ... (GAAP) loss per share from continuing operations ... increased 16 percent to $110 million ... percent to $161 million ... continuing operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... DUBLIN , Aug. 7, 2017  Endo International ... has reached agreements to resolve virtually all known U.S. ... in discussions to resolve the known remaining U.S. claims ... installment payments beginning in the fourth quarter of 2017 ... part of its second quarter 2017 results, the Company ...
(Date:8/2/2017)... BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital in ... (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The new addition, ... uses UVC light energy to kill deadly pathogens such as C. diff , MRSA, ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
Breaking Medicine Technology: